Synektik Sa · GPW:SNT
Synektik Sa — Investor Day (April 2026)
29 slides from Synektik Sa's investor day presentation, Apr 21, 2026
Slide 1: Growth prospects for Synektik Group in Poland and the region
SYNEKTIK CAPITAL MARKET DAY Growth prospects for Synektik Group in Poland and the region Cezary Kozanecki | Dariusz Korecki Warsaw | 21 April 2026 Synektik Capital Market Day | 21 April 2026 1
Slide 2: Transforming healthcare through technology
Transforming healthcare through technology Key factors driving growth in new technologies in healthcare ▪ Shortage of medical personnel There is a shortfall of about 10 million healthcare workers worldwide.1 Technology replaces and supports staff where they are lacking. ▪ Growing demand for precisio
Slide 3: Synektik is part of a global megatrend
Transforming healthcare through technology Synektik is part of a global megatrend CAGR 14.8% globally ▪ Surgical robotics USD bn CAGR 15.1% outside US 22,2 11,1 Global value of the surgical robotics market1 2024 2025 2026 2027 2028 2029 CAGR 4.5% total ▪ Imaging diagnostics USD bn CAGR 7.5% nuclear
Slide 4: Synektik Group
Synektik Group Business profile Integrator of innovative solutions for medicine ▪ Leading provider of advanced medical technologies ▪ Poland’s biggest producer and supplier of radiopharmaceuticals ▪ Producer of specialized medical software and applications ▪ Contractor for servicing and measuring su
Slide 5: Complementary solutions
Complementary solutions Areas at healthcare facilities ▪ Operating room ▪ Imaging diagnostics ▪ Radiotherapy ▪ Gynecology and obstetrics ▪ Hospital pharmacy ▪ Nuclear medicine ▪ IT infrastructure Synektik Capital Market Day | 21 April 2026 5
Slide 6: Ecosystem of modern diagnostic and treatment solutions
Synektik has created an ecosystem of modern diagnostic and treatment solutions Three pillars of the business Robotics in medicine ▪ Distribution, installation, servicing and support for robotics systems from a dozen or more ▪ 66% CAGR in recurring revenue in the last three years 631 leading global m
Slide 7: Surgical robotics – a rapidly growing market
Surgical robotics – a rapidly growing market Trends using the example of Intuitive Total no. of installations of Intuitive robots worldwide 18% 19% 20% 15% 17% 18% 20.4m+ 6,000 8,600 11,100 patients* 62% 59% 61% 5% 5% 6% 2020 2023 2025 USA Europe Asia Other USA Europe Asia Other Total CAGR 2020-2025
Slide 8: Region's largest platform for surgical robotics
We have built the region’s largest platform for surgical robotics Gdynia da Vinci systems in Poland, Czechia and Slovakia Gdańsk Grudziądz Wejherowo Słupsk Olsztyn 122 da Vinci systems under the care of 84 da Vinci systems Szczecin Bydgoszcz Toruń Białystok Wieliszew Biała Podlaska in Poland* Grodzi
Slide 9: Increasing territorial reach of cooperation with Intuitive
Increasing territorial reach of cooperation with Intuitive (since 2026) First da Vinci installations in the Baltic States this year (since 2025) 122 da Vinci systems (since 2025) under the care of Synektik Group (4Q 2025) 84 (since 2018) 30 (since 2022) (planned from 4Q 2026) 8 (since 2022) (date of
Slide 10: Exclusive distributor of da Vinci systems through 2031
Synektik Group – exclusive distributor of da Vinci systems in the region through 2031 Prolongation and expansion of contract with Intuitive Baltic States and Ukraine—market potential Lithuania, Poland Latvia & Ukraine ▪ Prolongation of cooperation agreement with Intuitive through Estonia the end of
Slide 11: Groundbreaking treatment for soft-tissue tumours
Expansion of offering with groundbreaking treatment for soft-tissue tumours Entering into cooperation with HistoSonics ▪ Synektik Group has become the exclusive distributor of Edison systems in Poland, Czechia, Slovakia, Lithuania, Latvia and Estonia ▪ The group will be responsible inter alia for sa
Slide 12: Robotics era in hospital pharmacies
Robotics era in hospital pharmacies Another segment of Synektik’s market—with the same growth logic Why are hospitals automating Global market for pharmacy robotics (USD bn)1 CAGR 7.1% globally their pharmacies? including c. 30% share for Europe 10,0 ▪ More medicines—hospitals are administering more
Slide 13: Robotization of hospital pharmacies
Robotization of hospital pharmacies Synektik is a distributor of BD Rowa pharmacy robots ▪ BD Rowa pharmacy robots ▪ Pharmacy robot automating the storage, filling and issuance of medicines at the hospital pharmacy; it eliminates errors in issuance, and reduces losses—the average cost of installing
Slide 14: Robotization of oncology hospitals
Robotization of oncology hospitals Synektik is a distributor of Apoteca robotic systems ▪ Apoteca robotic system from Loccioni ▪ Robot for production of cytotoxic medicines (chemotherapy). Drugs for cancer patients are prepared at hospitals, prior to administration. ▪ The robot protects staff from e
Slide 15: Radiopharmaceuticals
SYNEKTIK GROUP Radiopharmaceuticals Synektik Capital Market Day ||2121April April2026 2026 15
Slide 16: Poland's biggest producer and supplier of radiopharmaceuticals
Synektik Group is Poland’s biggest producer and supplier of radiopharmaceuticals Leader in production of special radiopharmaceuticals 55+ Products manufacturered by Synektik Group by Distribution of cyclotrons for production of diagnostic application radiopharmaceuticals used in PET scans no. of emp
Slide 17: Leading position on the growing radiopharmaceutical market
Synektik Group’s leading position on the steadily growing radiopharmaceutical market Revenue of the global nuclear Factors impacting the growth rate of the nuclear Use of radiopharmaceuticals medicine market (USD bn)1 medicine market* › Increased incidence of cancers and cardiovascular CAGR 11.3% di
Slide 18: Dividends
SYNEKTIK GROUP Dividends Synektik Capital Market Day ||2121April April2026 2026 18
Slide 19: Regular distribution of profit to shareholders
Regular distribution of profit to shareholders Growth in dividend potential thanks to increasing scale and division Synektik S.A. 10,75 Dividends paid ▪ Synektik has paid a dividend to shareholders every year since 2020 (the first for FY 2018). 8,25 102,9 ▪ In February 2026 the company paid out a re
Slide 20: Company and management recognized by the market
Synektik – company and management recognized by the market Open communications—vision—innovations—consistent striving for goals ▪ Awards for Synektik the company ▪ Awards for the company’s management board ▪ Best da Vinci distributor in the world—Intuitive ▪ CEO of the year, Bulls & Bears competitio
Slide 21: Financial results
SYNEKTIK GROUP Financial results Synektik Capital Market Day | 21 21April April2026 2026 21
Slide 22: Medical equipment and IT solutions
Medical equipment and IT solutions Revenue of the segment* (PLN mn) +45% Synektik Group’s leading business segment CAGR Growing share of recurring revenue is driving 579,1 630,8 growth in the profitability of the business 410,4 ▪ 60% CAGR in EBITDA and 45% CAGR in revenues of the segment 96,9 100,9
Slide 23: Promising prospects for future quarters
Medical equipment and IT solutions Promising prospects for future quarters Sales of medical equipment, orders to be filled, and active offers (PLN mn) PLN 239m Value of backlog and active offers at the end of 1Q of FY 2025 148,0 165,9 123,1 123,4 122,9 (+87% y/y) 114,0 73,2 ▪ Winning orders worth PL
Slide 24: Medical equipment and IT solutions
Medical equipment and IT solutions As the exclusive distributor of da Vinci systems in the region, Synektik Group is a direct beneficiary of the growing use of surgical robotics No. of surgical procedures assisted by da Vinci 10000 in Poland, Czechia and Slovakia, and installed devices (units) 122 C
Slide 25: Radiopharmaceuticals
Radiopharmaceuticals Revenue of the segment* Growth in sales and profitability (PLN mn) +12% CAGR ▪ 12% CAGR in revenue over the past 5 years, connected with rising demand for radiotracers and revision of 50,5 45,1 sale prices 36,5 28,5 27,7 28,9 ▪ 14% CAGR in EBITDA of the segment ▪ Growth in EBITD
Slide 26: Steady growth in recurring sales
Steady growth in recurring sales Stable business model with recurring revenue rising as a share of total revenue (increase from 31% in FY 2022 to 51% in FY 2024) Recurring sales compared to total revenue (PLN mn) 58% Total revenue CAGR in recurring revenue Revenue from sale of radiopharmaceuticals o
Slide 27: Consistent growth in EBITDA
Consistent growth in EBITDA Growing scale and repeat sales are driving the growth in profitability Adjusted EBITDA* for the past 4 quarters (PLN mn) 49% 187,0 CAGR in EBITDA over the past three years 177,8 156,3 143,0 146,4 Factors behind the growth in EBITDA: 141,0 140,9 134,2 120,2 ▪ Increase in r
Slide 28: Q&A session
SYNEKTIK GROUP Q&A session Synektik Capital Market Day ||2121April April2026 2026 28
Slide 29: Thank you for your attention!
WE INVITE YOU TO CONTACT US Thank you for your attention! Cezary Kozanecki CEO ckozanecki@synektik.com.pl Dariusz Korecki VP, CFO dkorecki@synektik.com.pl